{
    "id": 89,
    "premise": "none",
    "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC",
    "label": "entailment",
    "explanation": "US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC",
        "refined explanation": "US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
        "refined iteration": 0,
        "history explanation": [
            "0 iteration: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC.\nOlaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair."
        ],
        "history semantic validity": [
            "0 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 9.657404661178589, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'verit found a proof...', 'verit: Try this: using explanation_2 by blast (0.8 ms)', 'cvc4 found a proof...', 'vampire found a proof...', 'e found a proof...', 'zipperposition: Found duplicate proof', 'e: Found duplicate proof', 'cvc4: Found duplicate proof', 'zipperposition found a proof...', 'cvc4: Try this: using explanation_2 by presburger (2 ms)', 'vampire: Found duplicate proof', 'zipperposition: Found duplicate proof', 'Done'], 'code': 'theory clinical_89_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  USFDA :: \"entity \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Approve :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  TreatmentPurpose :: \"entity \u21d2 bool\"\\n  LicensedPARPInhibitor :: \"entity \u21d2 bool\"\\n  TumourDefects :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. USFDA x \u2227 (Olaparib y \u2228 Talazoparib y) \u2227 Approve e \u2227 Agent e x \u2227 Patient e y \u2227 TreatmentPurpose y\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y e. (Olaparib x \u2228 Talazoparib x) \u27f6 (LicensedPARPInhibitor x \u2227 TumourDefects y \u2227 Target e \u2227 Agent e x \u2227 Patient e y)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Olaparib x \u2228 Talazoparib x\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC. *)\\n  shows \"\u2200x. (Olaparib x \u2228 Talazoparib x) \u27f6 LicensedPARPInhibitor x\"\\nproof -\\n  (* From the assumption, we have Olaparib x or Talazoparib x. *)\\n  from asm have \"Olaparib x \u2228 Talazoparib x\" <ATP>\\n  (* Explanation 2 states that if Olaparib or Talazoparib, then they are Licensed PARP Inhibitors. *)\\n  (* This directly gives us the conclusion we need. *)\\n  then have \"LicensedPARPInhibitor x\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC (from Explanatory Sentence 1)\\nB: Olaparib and talazoparib are licensed PARP inhibitors (from Explanatory Sentence 2)\\nC: Olaparib and talazoparib target tumour specific defects in DNA repair (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, B & C)\\n--------\\n\\nDerived Implications:\\nImplies(Not(B), Not(A))\\nImplies(Not(Olaparib and talazoparib are licensed PARP inhibitors), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(Olaparib and talazoparib target tumour specific defects in DNA repair), Not(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC))\\n--------\\nImplies(A, C)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib target tumour specific defects in DNA repair)\\n--------\\nImplies(A, B)\\nImplies(US Food and Drug Administration approved olaparib and talazoparib for the treatment of patients with BRCA-mutated, HER-2-negative advanced or metastatic BC, Olaparib and talazoparib are licensed PARP inhibitors)\\n--------\\n'}"
        ]
    }
}